These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 29574749)

  • 1. Targeting EGFR-mediated autophagy as a potential strategy for cancer therapy.
    Sooro MA; Zhang N; Zhang P
    Int J Cancer; 2018 Nov; 143(9):2116-2125. PubMed ID: 29574749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polygonatum odoratum lectin induces apoptosis and autophagy via targeting EGFR-mediated Ras-Raf-MEK-ERK pathway in human MCF-7 breast cancer cells.
    Ouyang L; Chen Y; Wang XY; Lu RF; Zhang SY; Tian M; Xie T; Liu B; He G
    Phytomedicine; 2014 Oct; 21(12):1658-65. PubMed ID: 25442274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-targeting of EGFR and autophagy signaling is an emerging treatment strategy in metastatic colorectal cancer.
    Koustas E; Karamouzis MV; Mihailidou C; Schizas D; Papavassiliou AG
    Cancer Lett; 2017 Jun; 396():94-102. PubMed ID: 28323034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. w09, a novel autophagy enhancer, induces autophagy-dependent cell apoptosis via activation of the EGFR-mediated RAS-RAF1-MAP2K-MAPK1/3 pathway.
    Zhang P; Zheng Z; Ling L; Yang X; Zhang N; Wang X; Hu M; Xia Y; Ma Y; Yang H; Wang Y; Liu H
    Autophagy; 2017 Jul; 13(7):1093-1112. PubMed ID: 28513279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR-mediated autophagy in tumourigenesis and therapeutic resistance.
    Wu M; Zhang P
    Cancer Lett; 2020 Jan; 469():207-216. PubMed ID: 31639425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Future targeting of the RAS/RAF/MEK/ERK signaling pathway in oncology: the example of melanoma].
    Favre G
    Bull Acad Natl Med; 2014 Feb; 198(2):321-36; discussion 337-8. PubMed ID: 26263707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR signaling and autophagy dependence for growth, survival, and therapy resistance.
    Jutten B; Rouschop KM
    Cell Cycle; 2014; 13(1):42-51. PubMed ID: 24335351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK.
    Martinelli E; Morgillo F; Troiani T; Ciardiello F
    Cancer Treat Rev; 2017 Feb; 53():61-69. PubMed ID: 28073102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR inhibitors and autophagy in cancer treatment.
    Cui J; Hu YF; Feng XM; Tian T; Guo YH; Ma JW; Nan KJ; Zhang HY
    Tumour Biol; 2014 Dec; 35(12):11701-9. PubMed ID: 25293518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging MEK inhibitors.
    McCubrey JA; Steelman LS; Abrams SL; Chappell WH; Russo S; Ove R; Milella M; Tafuri A; Lunghi P; Bonati A; Stivala F; Nicoletti F; Libra M; Martelli AM; Montalto G; Cervello M
    Expert Opin Emerg Drugs; 2010 Jun; 15(2):203-23. PubMed ID: 20151845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOXD3 is a tumor suppressor of colon cancer by inhibiting EGFR-Ras-Raf-MEK-ERK signal pathway.
    Li K; Guo Q; Yang J; Chen H; Hu K; Zhao J; Zheng S; Pang X; Zhou S; Dang Y; Li L
    Oncotarget; 2017 Jan; 8(3):5048-5056. PubMed ID: 27926503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS-related proteins in pancreatic cancer.
    Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
    Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T11TS inhibits Angiopoietin-1/Tie-2 signaling, EGFR activation and Raf/MEK/ERK pathway in brain endothelial cells restraining angiogenesis in glioma model.
    Bhattacharya D; Chaudhuri S; Singh MK; Chaudhuri S
    Exp Mol Pathol; 2015 Jun; 98(3):455-66. PubMed ID: 25797371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing.
    Oh YT; Deng J; Yue P; Owonikoko TK; Khuri FR; Sun SY
    Oncogene; 2016 Jan; 35(4):459-67. PubMed ID: 25867065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
    Roberts PJ; Der CJ
    Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting cathepsin S induces tumor cell autophagy via the EGFR-ERK signaling pathway.
    Chen KL; Chang WS; Cheung CH; Lin CC; Huang CC; Yang YN; Kuo CP; Kuo CC; Chang YH; Liu KJ; Wu CM; Chang JY
    Cancer Lett; 2012 Apr; 317(1):89-98. PubMed ID: 22101325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer.
    Brechbiel J; Miller-Moslin K; Adjei AA
    Cancer Treat Rev; 2014 Jul; 40(6):750-9. PubMed ID: 24613036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.
    McCubrey JA; Milella M; Tafuri A; Martelli AM; Lunghi P; Bonati A; Cervello M; Lee JT; Steelman LS
    Curr Opin Investig Drugs; 2008 Jun; 9(6):614-30. PubMed ID: 18516761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of downstream signaling pathways of the epidermal growth factor receptor for Artesunate's activity in cancer cells.
    Konkimalla VB; McCubrey JA; Efferth T
    Curr Cancer Drug Targets; 2009 Feb; 9(1):72-80. PubMed ID: 19200051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.